Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin B3 pill may boost aging brains, new study hopes

NCT ID NCT05483465

Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily dose of nicotinamide riboside (a form of vitamin B3) can improve blood flow and activity in the brains of healthy adults aged 60 to 85. Over 8 weeks, 214 participants will take either the supplement or a placebo. Researchers will measure brain blood flow and electrical activity to see if the supplement helps keep the aging brain healthier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotinamide riboside (a form of vitamin B3)
What this could lead to
If it works, this could point toward a simple supplement to help maintain brain health and memory in older adults.
What could go wrong
This is a relatively small, early-phase trial focused on measuring blood flow changes, not memory or thinking ability directly. The supplement may not produce noticeable benefits, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 214 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥60 and ≤85 years of age * Adequate hearing and visual acuity to participate in the examinations * Ability to read and write in English * Competence to provide informed consent. * Mini-Mental State Exam score ≥24 Exclusion Criteria: * Vision or hearing impairment that would impair the ability to complete study assessments * Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer * Cerebrovascular accident other than TIA within 60 days prior to Visit 0 * Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse * Abnormal kidney function (creatinine \>2mg/dL or EGFR \<30mL/min) by most recent labs within 6 months prior to Visit 0 * Elevated liver enzymes (AST and/or ALT above x2 upper limit of normal) by most recent labs within 6 months prior to Visit 0 * Treatment with other NAD enhancers (Nicotinamide riboside or nicotinamide mononucleotide) within 4 weeks prior to randomization. * Any other medical condition which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.